$605.6 M

CASI Mkt cap, 11-Jul-2018
CASI Pharmaceuticals Net income (Q1, 2018)-3.6 M
CASI Pharmaceuticals Cash, 31-Mar-201849.9 M
CASI Pharmaceuticals EV557.2 M

CASI Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.7 k47.7 k

Revenue growth, %

101%

Cost of goods sold

7.5 k6.3 k

Gross profit

16.3 k41.4 k

Gross profit Margin, %

69%87%

R&D expense

2.8 m4.1 m4.6 m

General and administrative expense

3.8 m3.1 m4.8 m

Operating expense total

26.2 m7.2 m9.4 m

Interest expense

26.6 k81.5 k26.1 k

Interest income

81.5 k

Net Income

(5.7 m)(26.2 m)(7.2 m)(9.5 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cost of goods sold

6.3 k2.7 k

R&D expense

793.8 k560 k724.5 k697 k865 k1.2 m942.3 k1 m1.4 m1 m1 m1.7 m971 k1.7 m

General and administrative expense

648.7 k891.4 k891.9 k1.2 m924.8 k857.6 k673.9 k765.1 k1.9 m676.9 k644.2 k691.4 k625.9 k1.3 m

Operating expense total

1.4 m1.5 m1.6 m1.8 m1.8 m2.1 m1.6 m1.8 m3.3 m1.7 m1.7 m2.4 m1.6 m3 m

Depreciation and amortization

69.4 k

Interest expense

24.2 k24.3 k24.3 k8.8 k8.8 k5.6 k546

Interest income

384 129 6.7 k

Net Income

(1.4 m)(1.5 m)(1.6 m)(21.5 m)(1.8 m)(2.1 m)(1.6 m)(1.8 m)(3.3 m)(1.7 m)(1.7 m)(2.4 m)(1.6 m)(3.6 m)

CASI Pharmaceuticals Balance Sheet

Annual

USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

6.3 m4.9 m1.1 m8 m15.1 m10.7 m5.1 m27.1 m

Accounts Receivable

Inventories

Current Assets

15.4 m11 m5.6 m27.4 m

PP&E

78.1 k261.8 k218.8 k229.6 k

Total Assets

15.5 m11.3 m5.8 m27.7 m

Accounts Payable

402.5 k754.6 k884.1 k1.1 m

Short-term debt

Current Liabilities

565.2 k919 k1.1 m1.3 m

Long-term debt

Total Debt

Total Liabilities

6.9 m

Additional Paid-in Capital

421.8 m432.6 m434.1 m470.1 m

Retained Earnings

(399.1 m)(425.3 m)(432.5 m)(441.9 m)

Total Equity

14.9 m(422.2 k)20.8 m

Shares Outstanding

28.6 m32.4 m

Financial Leverage

1 x-26.8 x1.3 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

15.9 m14.2 m13.1 m11.8 m9.5 m8 m6.4 m13.9 m18.5 m24.1 m25.5 m23.4 m21.6 m49.9 m

Current Assets

16.2 m14.5 m13.2 m12.2 m9.9 m8.3 m6.8 m14.3 m18.8 m24.5 m25.9 m23.6 m22.1 m52.1 m

PP&E

56.6 k113.7 k240.4 k230.6 k246.3 k245.3 k234.7 k222.8 k168.7 k184.1 k244.6 k448.5 k566 k1.2 m

Total Assets

16.3 m14.6 m13.5 m12.4 m10.2 m8.6 m7.1 m14.5 m19 m24.8 m26.2 m24.1 m22.7 m71.2 m

Accounts Payable

352.3 k591.7 k573.5 k600.2 k994.9 k969 k801.3 k783.3 k945.8 k918.9 k1.1 m1.2 m1.2 m1.6 m

Short-term debt

1.5 m

Current Liabilities

501.4 k755.9 k743.4 k764.2 k2.6 m2.6 m971 k2.4 m2.6 m2.6 m2.8 m3 m3 m2 m

Total Debt

1.5 m

Total Liabilities

11.6 m12 m12 m11.8 m9.9 m8.9 m8.7 m6.9 m7.1 m7.1 m3.5 m

Additional Paid-in Capital

421.3 m422.1 m422.6 m432.2 m433 m433.4 m433.8 m446.5 m455.1 m456.5 m470.3 m470.5 m470.7 m529.4 m

Retained Earnings

(397.8 m)(400.5 m)(402.1 m)(423.7 m)(427.1 m)(429.2 m)(430.8 m)(434.3 m)(437.6 m)(439.3 m)(443.6 m)(446 m)(447.7 m)(455.1 m)

Total Equity

15.8 m13.9 m12.7 m837.7 k(1.8 m)(3.4 m)(4.7 m)4.6 m10 m16 m19.2 m17 m15.6 m67.6 m

Financial Leverage

1 x1.1 x1.1 x14.8 x-5.6 x-2.5 x-1.5 x3.1 x1.9 x1.5 x1.4 x1.4 x1.5 x1.1 x

CASI Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016

Net Income

(26.2 m)(7.2 m)(9.5 m)

Depreciation and Amortization

48.2 k68.4 k66.5 k

Accounts Receivable

(23.7 k)23.7 k

Inventories

Accounts Payable

352.2 k129.5 k180.5 k

Cash From Operating Activities

(4 m)(5.5 m)(6 m)

Cash From Investing Activities

(466.3 k)(25.4 k)(64.8 k)

Cash From Financing Activities

28 m

Interest Paid

7.5 k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(4.4 m)(1.5 m)(3.1 m)(24.6 m)(1.8 m)(2.1 m)(1.6 m)(1.8 m)(3.3 m)(1.7 m)(1.7 m)(3.6 m)

Depreciation and Amortization

12.9 k6.5 k19.2 k32.7 k65.8 k

Accounts Receivable

669.3 k

Accounts Payable

(152.6 k)189.3 k171.1 k197.8 k994.9 k969 k801.3 k783.3 k945.8 k918.9 k1.1 m(522.3 k)

Cash From Operating Activities

(2.6 m)(890.1 k)(1.9 m)(2.9 m)(5.4 m)

Purchases of PP&E

(155.1 k)

Cash From Investing Activities

(16.9 k)(42.1 k)(181.4 k)(419.6 k)(19.3 m)

Cash From Financing Activities

10.4 m30.7 m

CASI Pharmaceuticals Ratios

USDY, 2018

EV/CFO

-103.1 x

Financial Leverage

1.1 x
Report incorrect company information